ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Bliss GVS Pharma was fined Rs. 1,80,000 (excluding GST) by BSE and NSE for failing to appoint a woman director. The fine has been paid to the regulators.
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
Bliss GVS Pharma Ltd reported revenue from operations of ₹313.4 Cr (+28.2% YoY) and net profit of ₹53.3 Cr (+86.4% YoY) for Q2 FY27.
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bliss GVS Pharma Ltd scheduled a board meeting for October 29, 2026, to approve the company's unaudited financial results for the quarter ending September 30, 2026.
Bliss GVS Pharma Ltd has filed its quarterly shareholding pattern report for the period ended September 30, 2026.
Bliss GVS Pharma has issued a postal ballot notice to seek member approval for the appointment of three directors. This follows a recent change in control.
Bliss GVS Pharma Limited allotted 53,500 equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's total paid-up share capital.
Bliss GVS Pharma announced the reclassification of its erstwhile promoter group to the public category following a change in control via an open offer.
Promoter Mates Visa Consultancy pledged 5.1 crore shares of Bliss GVS Pharma valued at ₹3,487.35 Crore. This pledge creates leverage on the promoter's stake.
Bliss GVS Pharma's promoters pledged 5,09,84,595 equity shares (47.95%) in favour of Catalyst Trusteeship as Debenture Trustee on 30 Sep 2026. No loan or consideration amount is disclosed in the filing.
Bliss GVS Pharma's board approved the adoption of two new Employee Stock Option Policies: Senior Executive ESOP 2026 and Employee ESOP 2026.
Anupam Rasayan India Limited and PAC acquired a 50.07% stake in Bliss GVS Pharma Limited. The acquisition follows a Share Purchase Agreement and Open Offer completion.
Bliss GVS Pharma Limited appointed Hetul Mehta, Amar Shah, and Pramod Kasat as Non-Executive Directors. Simultaneously, Narsimha Shibroor Kamath resigned as Executive Director effective September 28, 2026.
Bliss GVS Pharma Ltd has scheduled a board meeting for October 01, 2026, to consider establishing new Employee Stock Option Plans.
Bliss GVS Pharma announced a change in control, with Anupam Rasayan India and Mates Visa Consultancy becoming the new promoters. The board also reconstituted the leadership team.
Bliss GVS Pharma Ltd reported the voting results of its postal ballot. Members approved the appointment of Mr. Santosh Parab as a Non-Executive and Non-Independent Director.
Bliss GVS Pharma allotted equity shares under its Employee Stock Option Scheme (ESOP). This increases the company's total paid-up share capital.
Bliss GVS Pharma allotted 55,250 equity shares under its Employee Stock Option Plan 2019 at an exercise price of Rs. 43 per share.
Anupam Rasayan India Ltd completed an open offer to acquire 26% of Bliss GVS Pharma Ltd. Only 1,669 shares were acquired for ₹4.99 Lakh.
Bliss GVS Pharma Ltd issued a Postal Ballot Notice to seek shareholder approval for the appointment of Mr. Santosh Parab as a Director.
Bliss GVS Pharma Ltd reported revenue from operations of ₹285.6 Cr (+37.6% YoY) and net profit of ₹51.4 Cr (+15.8% YoY) for Q1 FY27.